Despite their increased enrollment into medical school, women still face systemic barriers in medicine, whether in an academic or nonacademic setting. Those from Under-Represented Minority (URM) groups face similar issues, which may affect their desire to enter, pursue, and/or maintain a career in medicine. Social media provides unique opportunities for peer-to-peer support among members of URM communities and for amplification of their voices calling for social justice-here defined as a redistribution of power and the quest for equity in access to opportunities, including access to mentorship, professional development, and timely promotion in academic rank. These issues are relevant to oncologists especially as we strive for diversity, equity, and inclusion and to ensure that our patients have equal access to care, regardless of their circumstances. In this article, we review current literature that highlights issues faced by women and historically URM groups in medicine, particularly in oncology. We also discuss the physician's role as a social justice advocate and the concept of the public physician., Competing Interests: Narjust FlorezConsulting or Advisory Role: AstraZeneca, Pfizer, NeoGenomics Laboratories, Janssen, Bristol Myers Squibb/Medarex, Merck, Mirati TherapeuticsSpeakers' Bureau: MJH Life Sciences Maimah KarmoConsulting or Advisory Role: Seattle Genetics, Bayer, Lilly (Inst) Elizabeth HenryEmployment: theMednetConsulting or Advisory Role: Seattle Genetics/AstellasResearch Funding: Seattle Genetics/Astellas (Inst), Bristol Myers Squibb (Inst), Nektar (Inst)Other Relationship: theMednet Matthew S. KatzEmployment: Radiation Oncology AssociatesStock and Other Ownership Interests: Dr Reddy's Laboratories, Healthcare Services Group, CVS Health, Hologic, PfizerOpen Payments Link: https://openpaymentsdata.cms.gov/physician/1027599 Don S. DizonThis author is a member of the Journal of Oncology Practice Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: i-Mab, Clovis Oncology, AstraZeneca, Regeneron, Tesaro, Pfizer, Oasmia Pharmaceutical ABResearch Funding: Bristol Myers Squibb (Inst), Kazia Therapeutics (Inst), Pfizer (Inst)Open Payments Link: https://openpaymentsdata.cms.gov/physician/744193/summary Heather M. HyltonThis author is a member of the Journal of Oncology Practice Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.No other potential conflicts of interest were reported.